Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, Florida.
Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
Clin Cancer Res. 2024 Jun 3;30(11):2333-2341. doi: 10.1158/1078-0432.CCR-23-0409.
Bruton's tyrosine kinase (BTK) is central to the survival of malignant and normal B lymphocytes and has been a crucial therapeutic target of several generations of kinase inhibitors and newly developed degraders. These new means for targeting BTK have added additional agents to the armamentarium for battling cancers dependent on B-cell receptor (BCR) signaling, including chronic lymphocytic leukemia and other non-Hodgkin lymphomas. However, the development of acquired resistance mutations to each of these classes of BTK inhibitors has led to new challenges in targeting BTK as well as novel insights into BCR signaling. The first-generation covalent BTK inhibitor ibrutinib is susceptible to mutations affecting the covalent binding site, cysteine 481 (C481). Newer noncovalent BTK inhibitors, such as pirtobrutinib, overcome C481 mutation-mediated resistance but are susceptible to other kinase domain mutations, particularly at residues Threonine 474 and Leucine 528. In addition, these novel BTK inhibitor resistance mutations have been shown biochemically and in patients to cause cross-resistance to some covalent BTK inhibitors. Importantly, newer generation covalent BTK inhibitors zanubrutinib and acalabrutinib are susceptible to the same mutations that confer resistance to noncovalent inhibitors. The BTK L528W mutation is of particular interest as it disrupts the kinase activity of BTK, rendering it kinase dead. This observation suggests that BTK may act independently of its kinase activity as a scaffold. Thus, the timely development of BTK degrading proteolysis targeting drugs has allowed for degradation, rather than just enzymatic inhibition, of BTK in B-cell lymphomas, and early clinical trials to evaluate BTK degraders are underway.
布鲁顿酪氨酸激酶(BTK)是恶性和正常 B 淋巴细胞存活的核心,已成为几代激酶抑制剂和新开发的降解剂的关键治疗靶点。这些针对 BTK 的新方法为依赖 B 细胞受体(BCR)信号的癌症增加了更多的药物,包括慢性淋巴细胞白血病和其他非霍奇金淋巴瘤。然而,每种 BTK 抑制剂类别的获得性耐药突变的发展给 BTK 的靶向带来了新的挑战,也为 BCR 信号提供了新的见解。第一代共价 BTK 抑制剂伊布替尼易受影响共价结合位点半胱氨酸 481(C481)的突变影响。更新的非共价 BTK 抑制剂,如 pirtobrutinib,克服了 C481 突变介导的耐药性,但易受其他激酶结构域突变的影响,特别是在残基苏氨酸 474 和亮氨酸 528。此外,这些新的 BTK 抑制剂耐药突变已在生化和患者中显示出导致对一些共价 BTK 抑制剂的交叉耐药性。重要的是,更新一代的共价 BTK 抑制剂 zanubrutinib 和 acalabrutinib 易受赋予非共价抑制剂耐药性的相同突变影响。BTK L528W 突变特别有趣,因为它破坏了 BTK 的激酶活性,使其激酶失活。这一观察结果表明,BTK 可能独立于其激酶活性作为支架发挥作用。因此,BTK 降解蛋白水解靶向药物的及时开发允许在 B 细胞淋巴瘤中降解 BTK,而不仅仅是酶抑制,并且正在进行早期临床试验来评估 BTK 降解剂。